Current NDC auxiliary source row compounder:2187

This page is keyed by dataset, FDA.report source record ID, and physical source row number. Empty values are shown rather than omitted.

Complete normalized row#

Record Source: ndc_compounder_zip
Product Ndc Raw: 72627-2323
Product Ndc: 72627-2323
Product Ndc Digits: 726272323
Product Type Name: HUMAN COMPOUNDED DRUG
Proprietary Name: Tirzepatide/Niacinamide
Proprietary Name Suffix: [empty]
Nonproprietary Name: Tirzepatide/Niacinamide
Dosage Form Name: INJECTION
Route Name: SUBCUTANEOUS
Marketing Category Name: OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)
Labeler Name: Empower Pharma
Establishment Name: Empower Pharma
Establishment Fei: [empty]
Substance Name: TIRZEPATIDE; NIACINAMIDE
Active Ingredients Info: 8 mg/1 mL; 2 mg/1 mL
History Active Ingredients Raw: TIRZEPATIDE; NIACINAMIDE
History Active Ingredients Info Raw: 8 mg/1 mL; 2 mg/1 mL
History Dosage Raw: INJECTION
Dea Schedule: [empty]
Package Ndc Raw: 72627-2323-6
Package Ndc: 72627-2323-6
Package Ndc Digits: 7262723236
Package Ndc11: 72627232306
Package Description: 2.5 mL in 1 VIAL, MULTI-DOSE (72627-2323-6)
Reporting Period Raw: 2025-1
Reporting Period: 2025-1
Normalization Status: valid
Source Url: https://www.accessdata.fda.gov/cder/compounders_ndc_directory.zip
Source Archive: compounders_ndc_directory.zip
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Last Modified: Fri, 18 Sep 2026 15:17:23 GMT
Source Archive Sha256: 222f6800f79cb1a0fa79431b7226bd6b34899999dbf086af51004a96774ada98
Source Member Sha256: f8d9743e5616579a34d614887e86a53913efa0a63d3138d59d2f87cbb4d0cc17
Source Record Id: compounder:2187
Source Row Number: 2187
Source Row Hash: f766c6b0f2de48725982ab02ba2c5b3967075993eabce725e10beed2d369ca5f
Import Run Id: 20261024T140201Z
Loaded At: 2026-10-24 14:07:01

Exact raw FDA source fields#

{
    "ROUTENAME": "SUBCUTANEOUS",
    "PRODUCTNDC": "72627-2323",
    "DEASCHEDULE": "",
    "LABELERNAME": "Empower Pharma",
    "SUBSTANCENAME": "TIRZEPATIDE; NIACINAMIDE",
    "DOSAGEFORMNAME": "INJECTION",
    "NDCPACKAGECODE": "72627-2323-6",
    "PRODUCTTYPENAME": "HUMAN COMPOUNDED DRUG",
    "PROPRIETARYNAME": "Tirzepatide/Niacinamide",
    "REPORTINGPERIOD": "2025-1",
    "NONPROPRIETARYNAME": "Tirzepatide/Niacinamide",
    "PACKAGEDESCRIPTION": "2.5 mL in 1 VIAL, MULTI-DOSE (72627-2323-6) ",
    "ACTIVEINGREDIENTSINFO": "8 mg/1 mL; 2 mg/1 mL",
    "MARKETINGCATEGORYNAME": "OUTSOURCING FACILITY COMPOUNDED HUMAN DRUG PRODUCT (EXEMPT FROM APPROVAL REQUIREMENTS)",
    "PROPRIETARYNAMESUFFIX": ""
}

Normalization notes#

[]

Current status projection#

Dataset: compounder
Record Source: ndc_compounder_zip
Source Record Id: compounder:2187
Source Row Number: 2187
Status Scope: package
Lookup Ndc: 72627-2323-6
Lookup Ndc Digits: 7262723236
Product Ndc: 72627-2323
Product Ndc Digits: 726272323
Package Ndc: 72627-2323-6
Package Ndc Digits: 7262723236
Package Ndc11: 72627232306
Product Id: [empty]
Status Code: COMPOUNDER
Status Label: Outsourcing facility compounded drug report
Reporting Period Raw: 2025-1
Reporting Period: 2025-1
Source Table: fda_ndc_aux_compounder
Source File: compounders_ndc_directory.txt
Source Date: 2026-09-18
Source Row Hash: f766c6b0f2de48725982ab02ba2c5b3967075993eabce725e10beed2d369ca5f
Import Run Id: 20261024T140201Z
Loaded At: 2026-10-24 14:07:01